Erratum: Vol. 71, No. 45

Published on January 19, 2023

Erratum for MMWR Vo. 71, No. 45

Continue reading on website
Other news

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023

January 12, 2023
This report describes similar early safety findings from the Vaccine Adverse Event Reporting System for bivalent booster vaccination in children aged 5-11 years as the monovalent booster vaccination.

EARLY RELEASE: Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Acce...

January 25, 2023
This report describes how a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2-4 monovalent vaccine doses.